The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

(2009) S. Branford et al.   BLOOD

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2009) Timothy Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib

(2009) E Lierman et al.   LEUKEMIA

Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders

(2008) Nicholas C.P. Cross et al.   ACTA HAEMATOLOGICA

Molecular Pathobiology of Gastrointestinal Stromal Sarcomas

(2008) Christopher L. Corless et al.   Annual Review of Pathology-Mechanisms of Disease

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation

(2008) B. Dewaele et al.   CLINICAL CANCER RESEARCH

Primary resistance to imatinib in Fip1-like 1–platelet-derived growth factor receptor α—positive eosinophilic leukemia

(2008) Dagmar Simon et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions

(2008) J Score et al.   LEUKEMIA

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

(2008) J Gotlib et al.   LEUKEMIA